Clinically relevant measures of fit? A note of caution.

Risk reclassification methods have become popular in the medical literature as a means of comparing risk prediction models. In this issue of the Journal, Pencina et al. (Am J Epidemiol. 2012;176(6):492-494) present further results for continuous measures of model discrimination and describe their characteristics in nested models with normally distributed variables. Measures include the change in the area under the receiver operating characteristic curve, the integrated discrimination improvement, and the continuous net reclassification improvement. Although theoretically interesting, these continuous measures may not be the most appropriate to assess clinical utility. The continuous net reclassification improvement, in particular, is a measure of effect rather than model improvement and can sometimes exhibit erratic behavior, as illustrated in 2 examples. Caution is needed before using this as a measure of improvement. Further, the test of the continuous net reclassification improvement and that for the integrated discrimination improvement are similar to the likelihood ratio test in nested models and may be overinterpreted. Reclassification in risk strata, while requiring thresholds, may be more relevant clinically with its ability to examine potential changes in treatment decisions.

[1]  Nancy R Cook,et al.  Comments on ‘Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers’ by M. J. Pencina, R. B. D'Agostino, Sr. and E. W. Steyerberg , 2012, Statistics in medicine.

[2]  David A. Hinds,et al.  Assessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical Information , 2010, Journal of the National Cancer Institute.

[3]  J. Cuzick,et al.  American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Pencina,et al.  Interpreting incremental value of markers added to risk prediction models. , 2012, American journal of epidemiology.

[5]  N. Cook,et al.  Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. , 2007, JAMA.

[6]  J. Cuzick,et al.  American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  N. Cook Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[8]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[9]  J. Shaughnessy,et al.  Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. , 2011, Blood.

[10]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[11]  K. Thursky,et al.  Use of risk stratification to guide ambulatory management of neutropenic fever , 2011, Internal medicine journal.

[12]  Khan Aa,et al.  Risk stratification after acute myocardial infarction. , 2001, JPMA. The Journal of the Pakistan Medical Association.

[13]  Nancy R Cook,et al.  The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women , 2006, Annals of Internal Medicine.

[14]  Holly Janes,et al.  Commentary: Reporting standards are needed for evaluations of risk reclassification. , 2011, International journal of epidemiology.

[15]  Paul M. Ridker,et al.  Development and Validation of Improved Algorithms for the Assessment of Global Cardiovascular Risk in Women , 2007 .

[16]  J. Kassirer,et al.  Therapeutic decision making: a cost-benefit analysis. , 1975, The New England journal of medicine.

[17]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[18]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[19]  C. Begg,et al.  One statistical test is sufficient for assessing new predictive markers , 2011, BMC Medical Research Methodology.

[20]  Nancy R Cook,et al.  Performance of reclassification statistics in comparing risk prediction models , 2011, Biometrical journal. Biometrische Zeitschrift.